Synonyms: AZD-2624 | AZD4901 | MLE4901
Compound class:
Synthetic organic
Comment: Pavinetant (AZD2624) is an orally active antagonist of neurokinin receptor 3 (TACR3) developed initially by AstraZeneca as a potential therapeutic for schizophrenia. This compound was included in AstaZeneca's Open Innovation Pharmacology Toolbox (but has since been removed). Later renamed to AZD4901 it was acquired by Millendo Therapeutics who gave it a new research code of MLE4901 for their development programs for polycystic ovary syndrome and menopausal hot flushes. A successful Phase 2 study for the latter indication was reported in April 2017 [5]. A total of eight analogues are disclosed in the AstraZeneca composition of matter filing [6],
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
As AZD2624 the compound failed in a schizophrenia proof-of-principle study [3] (see NCT00686998). A trial of AZD4901 for polycystic ovary syndrome (PCOS) was reported in 2016 [2] (see NCT01872078). As MLE4901 this compound has completed Phase 2 clinical trial for management of menopausal hot flushes [5]. MLE4901 was found to be safe and effective in this trial (see NCT02668185). A Phase 2 study for the treatment of PCOS (NCT02865915) was terminated because the risk/benefit profile did not warrant continued development. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02668185 | Neuropeptide Treatment for Hot Flushes During the Menopause | Phase 2 Interventional | Imperial College London | 4-5 | |
NCT00686998 | Phase IIA Study in Patients With Schizophrenia | Phase 2 Interventional | AstraZeneca | ||
NCT01872078 | A Study of AZD4901 in Females With Polycystic Ovary Syndrome | Phase 2 Interventional | AstraZeneca | ||
NCT02865915 | MLE4901 vs. Placebo for the Treatment of PCOS | Phase 2 Interventional | Millendo Therapeutics, Inc. |